戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  effects of many missense mutations of human aspartoacylase.
2 partoacylase protein levels and undetectable aspartoacylase activity.
3 tures revealed that the N-terminal domain of aspartoacylase adopts a protein fold similar to that of
4 myosin-1d interacts and is co-expressed with aspartoacylase, an enzyme that plays a key role in fatty
5 oss of catalytic activity, thus establishing aspartoacylase as a zinc metalloenzyme.
6                      It is demonstrated that aspartoacylase (ASP gene) and succinylglutamate desuccin
7 nked to mutations in the gene for the enzyme aspartoacylase (ASPA) (EC 3.5.1.15).
8 anavan disease is a leukodystrophy caused by aspartoacylase (ASPA) deficiency.
9                                              Aspartoacylase (ASPA) is an oligodendrocyte-restricted e
10               Recent studies have shown that aspartoacylase (ASPA), the defective enzyme in Canavan d
11                      NAA and NAAG as well as aspartoacylase (ASPA), the enzyme responsible for NAA de
12                    Mutations in the gene for aspartoacylase (ASPA), which catalyzes deacetylation of
13 ed perturbed metabolic regulators, including aspartoacylase (Aspa), which facilitates generation of a
14 ethal leukodystrophy caused by deficiency in aspartoacylase (ASPA), which hydrolyzes N-acetylaspartat
15                                              Aspartoacylase (ASPA)-deficient patients [Canavan diseas
16  (AAV)-based plasmids containing recombinant aspartoacylase (ASPA).
17 ve trait that is caused by the deficiency of aspartoacylase (ASPA).
18                                              Aspartoacylase (ASPA; EC 3.5.1.15) catalyzes deacetylati
19 tested a three-dimensional homology model of aspartoacylase based on zinc dependent carboxypeptidase
20                                              Aspartoacylase catalyzes hydrolysis of N-acetyl-l-aspart
21                                              Aspartoacylase catalyzes the deacetylation of N-acetylas
22 eviously shown to block brain vacuolation in aspartoacylase-deficient mice, also prevents neuron loss
23             About 100 C-terminal residues of aspartoacylase form a globular domain with a two-strande
24                 The structure of human brain aspartoacylase has been determined in complex with a sta
25                                        Human aspartoacylase has now been successfully expressed in Pi
26                      These results show that aspartoacylase is a member of the caboxypeptidase A fami
27  hypothesize that the catalytic mechanism of aspartoacylase is closely analogous to that of carboxype
28 novel explanations for most loss-of-function aspartoacylase mutations associated with Canavan Disease
29 avan disease is caused by inactivating ASPA (aspartoacylase) mutations that prevent cleavage of N-ace
30                           Deglycosylation of aspartoacylase or mutation at the glycosylation site cau
31 (H21E/E24H and E24H/H116E) yielded wild-type aspartoacylase protein levels and undetectable ASPA acti
32  stabilization (R63N) also yielded wild-type aspartoacylase protein levels and undetectable aspartoac
33 y, and only E285A and P183H showed wild-type aspartoacylase protein levels.
34 stal structures of recombinant human and rat aspartoacylase refined to 2.8- and 1.8-A resolution, res
35                        The catalytic site of aspartoacylase shows close structural similarity to thos
36  with the Escherichia coli-expressed form of aspartoacylase suggested the need for a suitable eukaryo
37 onserved substrate-determining residues with aspartoacylase that, when mutated, cause Canavan disease
38 malfunctioning of a single metabolic enzyme, aspartoacylase, that catalyzes the deacetylation of N-ac
39 that result in near undetectable activity of aspartoacylase, which catalyzes the deacetylation of N-a

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。